Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSB11022 acetate versus citrate single-dose PK comparison in healthy volunteers
NL-OMON43181Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of idacio (2 arms), sponsored by Merck & Co. Primary endpoints: Concentration of investigational medicinal product in blood over time, Maximum concentration of investigational medicinal product in blood and 1 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
idacio
Beyond the preview
Go deeper on NL-OMON43181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43181.